NAMUR, Belgium, July 6, 2015 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has expanded its Scientific Advisory Board with the appointment of four prominent physician and industry experts. The additions of Jorge S. Reis-Filho, MD, PhD; Roland Andersson, MD, PhD; Stefan Holdenrieder, MD; and Stuart Blincko, PhD strengthen the clinical and commercial knowledge base of the company and reflect its rapidly advancing clinical development program.
Cameron Reynolds, Chief Executive Officer of VolitionRx, commented, "As we are currently undergoing several large clinical trials, testing our NuQ® cancer detection assays in studies involving more than 20,000 patients, we felt like it was time to give our current Scientific Advisory Board a strong clinical and industry focus. As we sharpen our strategy as a dynamic, clinical-stage company working to obtain CE Mark and market access, we look forward to the individual clinical expertise and valuable commercial guidance that Jorge, Roland, Stefan and Stuart will provide as members of our Scientific Advisory Board."
Dr. Jorge Reis-Filho, an experimental pathologist at Memorial Sloan Kettering Cancer Center in New York, focuses on massively parallel sequencing analysis of rare types of breast cancers for the development of a predictive molecular classification of the disease and on the characterization of intratumor genetic heterogeneity based on an integration of pathology methods, bioinformatics and single cell sequencing approaches.
Dr. Roland Andersson, Professor of Surgery and Vice-Dean of the Medical Faculty, Lund University, Sweden; and President of the Scandinavian Hepato-Pancreatico-Biliary Chapter, is a highly-experienced liver, biliary and pancreatic surgeon and oncologist who has authored more than 400 publications.
Dr. Stefan Holdenrieder, a senior physician and chemical pathologist at the University Hospital Bonn, is a leading authority on circulating nucleosomes in the blood and their origin and role in cancer.
Dr. Stuart Blincko, Senior Director of Assay R&D at U.S. company Immucor Inc., is an expert in the development of commercial ELISA products with experience gained at a number of companies including Immucor and most recently as Senior Principal Research Scientist at Abbott Laboratories.
Drs. Reis-Filho, Andersson, Holdenrieder and Blincko join Chair of the Volition Scientific Advisory Board Dr. Alan Colman and original SAB members Dr. Robert Weinzierl and Dr. Andreas Ladurner, expert scientists in genetics, epigenetics and chromosome and nucleosome structure in cancer.
Dr. Alan Colman, Chair of the Volition Scientific Advisory Board, said, "VolitionRx has effectively more than doubled its Scientific Advisory Board, which now includes specialists from across multiple scientific verticals including clinical and surgical expertise in cancer and pathology as well as commercial experience in ELISA product development with global diagnostic companies. Collectively, their wealth of knowledge and experience will be instrumental as we advance the NuQ® clinical programs, work to obtain regulatory approvals and prepare for market access and commercialization."
Clinical trials assessing the effectiveness of VolitionRx's assays include:
- A 4,800 patient retrospective symptomatic population study (Hvidovre Hospital, University of Copenhagen, Denmark)
- A 14,000 patient prospective screening study (Hvidovre Hospital, University of Copenhagen, Denmark)
- A 250 patient prospective study (CHU-UCL Mont Godinne Hospital, Belgium)
Pre-cancerous colorectal adenomas
- A 800 patient prospective study (Hvidovre Hospital, University of Copenhagen, Denmark)
27 most prevalent cancers
- A 4,200 patient prospective study that involves patients with the 27 most prevalent cancers (University Hospital, Bonn, Germany)
- A 600 patient prospective confirmatory study (University Hospital, Bonn, Germany)
- A retrospective study to establish the efficacy of VolitionRx's NuQ® tests to distinguish anaplastic prostate cancer, a particularly aggressive form of the disease, from typical castration resistant prostate cancer (CRPC), the less aggressive form (MD Anderson Cancer Center, Texas)
- A 120-patient prospective feasibility study (ImmuneHealth, Belgium)
- A 40-patient prospective feasibility study (Singapore General Hospital, Singapore)
- A prospective study to assess VolitionRx's NuQ® tests for the diagnosis of endometriosis (the University of Oxford, United Kingdom)
VolitionRx is a life sciences company focused on developing diagnostic tests for cancer and other conditions. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.
VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.
Anita Heward, VolitionRx
Telephone: +44 (0) 7756 034243
Kirsten Thomas, The Ruth Group
Telephone: +1 (646) 536-7014
Scott Powell, VolitionRx
Telephone: +1 (646) 650-1351
Lee Roth, The Ruth Group
Telephone: +1 (646) 536-7012
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of the Company's bodily-fluid-based diagnostic tests as well as the Company's ability to develop and successfully commercialize such test platforms for early detection of cancer. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include the Company's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company's development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
SOURCE VolitionRx Ltd